Bessemer Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bessemer Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5	Closed	-$1K	–	1744
2019 Q4	$1K	Hold	5	–	–	﹤0.01%	1611
2019 Q3	$0	Buy	+5	New	+$336	﹤0.01%	1846
2016 Q2	–	Sell	-65	Closed	-$8K	–	1482
2016 Q1	$8K	Buy	+65	New	+$7.67K	﹤0.01%	1176
2015 Q3	–	Sell	-24	Closed	-$6K	–	1767
2015 Q2	$6K	Buy	+24	New	+$6.39K	﹤0.01%	1338

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bessemer Group's ICPT Position: Q1 2020 in Review

Bessemer Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 5 shares — an estimated $1K sold.

Bessemer Group first reported a position in ICPT in Q2 2015 and held it in 4 quarters. The position peaked at $8K in Q1 2016. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

Bessemer Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Bessemer Group sold 5 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1K.
Bessemer Group first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2015 and held it in 4 quarters.
Bessemer Group's Intercept Pharmaceuticals, Inc. position peaked at $8K in Q1 2016.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Bessemer Group's 13F filing for Q1 2020, filed 30 Apr 2020.